These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. High-Density Lipoprotein Subclasses and Noncardiovascular, Noncancer Chronic Inflammatory-Related Events Versus Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis. Duprez DA; Otvos J; Tracy RP; Feingold KR; Greenland P; Gross MD; Lima JA; Mackey RH; Neaton JD; Sanchez OA; Jacobs DR J Am Heart Assoc; 2015 Sep; 4(9):e002295. PubMed ID: 26370448 [TBL] [Abstract][Full Text] [Related]
3. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia. Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506 [TBL] [Abstract][Full Text] [Related]
4. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. Vaziri ND J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569 [TBL] [Abstract][Full Text] [Related]
5. The paradox of dysfunctional high-density lipoprotein. Ansell BJ; Fonarow GC; Fogelman AM Curr Opin Lipidol; 2007 Aug; 18(4):427-34. PubMed ID: 17620860 [TBL] [Abstract][Full Text] [Related]
6. From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease. Sacks FM; Jensen MK Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):487-499. PubMed ID: 29371248 [TBL] [Abstract][Full Text] [Related]
7. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases. Ganjali S; Gotto AM; Ruscica M; Atkin SL; Butler AE; Banach M; Sahebkar A J Cell Physiol; 2018 Dec; 233(12):9237-9246. PubMed ID: 30076716 [TBL] [Abstract][Full Text] [Related]
8. High-density lipoprotein and atherosclerosis: the role of antioxidant activity. Bandeali S; Farmer J Curr Atheroscler Rep; 2012 Apr; 14(2):101-7. PubMed ID: 22441969 [TBL] [Abstract][Full Text] [Related]
9. Lipid disorders and their relevance to outcomes in chronic kidney disease. Vaziri ND; Norris K Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589 [TBL] [Abstract][Full Text] [Related]
13. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350 [TBL] [Abstract][Full Text] [Related]
14. Should we target HDL cholesterol level in lowering cardiovascular risk? Toth PP Pol Arch Med Wewn; 2009 Oct; 119(10):667-72. PubMed ID: 19847144 [TBL] [Abstract][Full Text] [Related]
16. HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research. Rohatgi A; Westerterp M; von Eckardstein A; Remaley A; Rye KA Circulation; 2021 Jun; 143(23):2293-2309. PubMed ID: 34097448 [TBL] [Abstract][Full Text] [Related]
17. High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. Kim SY; Yu M; Morin EE; Kang J; Kaplan MJ; Schwendeman A Arthritis Rheumatol; 2020 Jan; 72(1):20-30. PubMed ID: 31350818 [TBL] [Abstract][Full Text] [Related]
18. High-density Lipoprotein (HDL) Dysfunction and the Future of HDL. Ertek S Curr Vasc Pharmacol; 2018; 16(5):490-498. PubMed ID: 29149817 [TBL] [Abstract][Full Text] [Related]
19. Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. Brewer HB J Clin Endocrinol Metab; 2011 May; 96(5):1246-57. PubMed ID: 21389140 [TBL] [Abstract][Full Text] [Related]